The FDA cited non-sterile drug manufacturer PrecisionMed for ineffective cleaning to prevent cross-contamination of products at its Tampa, Florida facility.

The agency investigator cited the facility in a Form 483 for failing to properly clean work surfaces and utensils between batches.

The firm also failed to document cleaning procedures after manufacturing a highly potent drug compound, before producing a non-hazardous drug compound on the same equipment.